CA3186319A1 - Crystal forms of crenolanib and methods of use thereof - Google Patents

Crystal forms of crenolanib and methods of use thereof

Info

Publication number
CA3186319A1
CA3186319A1 CA3186319A CA3186319A CA3186319A1 CA 3186319 A1 CA3186319 A1 CA 3186319A1 CA 3186319 A CA3186319 A CA 3186319A CA 3186319 A CA3186319 A CA 3186319A CA 3186319 A1 CA3186319 A1 CA 3186319A1
Authority
CA
Canada
Prior art keywords
crystalline form
cancer
peaks
powder
crystalline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3186319A
Other languages
English (en)
French (fr)
Inventor
Vinay JAIN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arog Pharmaceuticals LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority claimed from PCT/US2021/033618 external-priority patent/WO2022019998A1/en
Publication of CA3186319A1 publication Critical patent/CA3186319A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA3186319A 2020-07-20 2021-05-21 Crystal forms of crenolanib and methods of use thereof Pending CA3186319A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063053921P 2020-07-20 2020-07-20
US63/053,921 2020-07-20
PCT/US2021/033618 WO2022019998A1 (en) 2020-07-20 2021-05-21 Crystal forms of crenolanib and methods of use thereof

Publications (1)

Publication Number Publication Date
CA3186319A1 true CA3186319A1 (en) 2022-01-27

Family

ID=79460325

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3186319A Pending CA3186319A1 (en) 2020-07-20 2021-05-21 Crystal forms of crenolanib and methods of use thereof

Country Status (4)

Country Link
EP (1) EP4181923A4 (https=)
JP (1) JP2023536068A (https=)
CN (1) CN113956245A (https=)
CA (1) CA3186319A1 (https=)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PA8580301A1 (es) * 2002-08-28 2005-05-24 Pfizer Prod Inc Nuevos derivados de benzoimidazol utiles como agentes antiproliferativos
EP1641780B1 (en) * 2003-06-24 2008-11-12 Pfizer Products Incorporated Processes for the preparation of 1- [(benzoimidazole-1yl) quinolin-8-yl] piperidin-4-ylamine derivatives
KR101738063B1 (ko) * 2012-09-21 2017-05-19 아로그 파마슈티칼스, 인코퍼레이티드 구조적으로 활성인 인산화된 ｆｌｔ３ 키나제의 억제 방법
TWI599356B (zh) * 2012-09-26 2017-09-21 安羅格製藥有限責任公司 抑制突變型ｃ－ｋｉｔ的方法
BR112015016282A2 (en) * 2013-01-07 2017-07-11 Arog Pharmaceuticals, Inc. crenolanib for treatment of mutated flt3 proliferative disorders
CN105294719B (zh) * 2015-11-18 2017-12-22 乳源瑶族自治县大众药品贸易有限公司 一种氨基喹唑啉类衍生物的二对甲苯磺酸盐及其晶型
EA201991078A1 (ru) * 2016-11-02 2019-11-29 Креноланиб для лечения пролиферативных расстройств, связанных с мутацией flt3
CN110840893A (zh) * 2018-12-13 2020-02-28 安罗格制药有限责任公司 含克莱拉尼的药物组合物及其用途

Also Published As

Publication number Publication date
CN113956245A (zh) 2022-01-21
EP4181923A4 (en) 2024-08-07
EP4181923A1 (en) 2023-05-24
JP2023536068A (ja) 2023-08-23

Similar Documents

Publication Publication Date Title
AU2008215384B2 (en) Crystalline forms of thiazolidinedione compound and its manufacturing method
RU2686722C1 (ru) Новые кристаллы урацильного соединения
CN101918418A (zh) 替诺福韦地索普西的固体形式
WO2024248083A1 (ja) キノリン置換化合物の結晶
KR20240000540A (ko) (s)-n-(3-(2-(((r)-1-하이드록시프로판-2-일)아미노)-6-모르폴리노피리딘-4-일)-4-메틸페닐)-3-(2,2,2-트리플루오로에틸)피롤리딘-1-카르복스아미드 및 이의 염의 고체 상태 형태
US12486256B2 (en) Crystal forms of crenolanib and methods of use thereof
CN114181161B (zh) (2-((取代氧基)苯基)氨基)嘧啶-4-基)氨基苯甲酰衍生物及其制备方法与应用
KR102531772B1 (ko) Cdk4/6 키나아제 억제제를 타겟팅하는 결정형
JP2024542840A (ja) Ｆｇｆｒ阻害剤の固体状形態
US12453722B2 (en) Maleate of nicotinyl alcohol ether derivative, crystal form thereof, and application thereof
US8772488B2 (en) Crystals of prasugrel hydrobromate
CA3186319A1 (en) Crystal forms of crenolanib and methods of use thereof
WO2012147832A1 (ja) フェニルピロール誘導体の結晶
TWI664172B (zh) 來那度胺的晶型及其製備方法和用途
CN101993417A (zh) 磷酸二甲啡烷的稳定新晶型
WO2023072263A1 (zh) 5-取代的吡啶-2(1h)-酮类化合物及其应用
WO2022256550A1 (en) Crystalline forms of an adenosine a2b receptor antagonist
TW202613103A (zh) 克萊拉尼的晶型及其使用方法
RU2336269C2 (ru) Кристаллическое индолсульфонамидное соединение и способ его получения
CN108752360B (zh) 一种治疗小儿腹泻的化合物及其制备方法
WO2022144042A1 (zh) Tas-116的晶型及其制备方法、药物组合物和用途
WO2026095022A1 (ja) キノリン置換化合物の結晶
WO2025242163A1 (zh) 蛋白激酶mek抑制剂的盐及其用途
JP2023535836A (ja) 線維芽細胞増殖因子受容体阻害剤の結晶形及びその調製方法
CN115772168A (zh) 苯并咪唑衍生物的多晶型物及其制备方法、药物组合物和用途

Legal Events

Date Code Title Description
P22 Classification modified

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P22-P110 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CLASSIFICATION MODIFIED

Effective date: 20241203

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250508

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250508

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20250521

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250521

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20250522

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250522

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250807

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20250807

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250807

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250807

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250807